Wolfhard Frost · Bessemerweg 13 · 33611 Bielefeld
E-Mail: info@prostata-sh.info

PSA Selbsthilfegruppe Prostatakrebs Bielefeld

mCRPC Dosisanpassung


mCRPC Wann die Dosis der Antikrebstherapie geändert werden sollte
Wesentliche Erkenntnisse und Empfehlungen

Prostatakrebs: Reduzierung einer Docetaxel-Dosis um 25% schmälert nicht den Überlebensvorteil

Quelle: Prostate. 2017 Jun 26. doi: 10.1002/pros.23378. [Epub ahead of print]
Dose considerations for anti-cancer drugs in metastatic prostate cancer.

Author information: Crumbaker, Gurney.
Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under-exposure of docetaxel and cabazitaxel; over-exposure of enzalutamide; and varied absorption of abiraterone acetate.
© 2017 Wiley Periodicals, Inc.

26.01.2018 Textlich laienverständlich aufbereitet für die PSA Selbsthilfegruppe Prostatakrebs Bielefeld e.V. von WDF